BPC-157 peptide injections: reconstitution, dosing, and evidence

Last updated 2026-07-23

What is a BPC-157 peptide injection, exactly

A BPC-157 injection is a subcutaneous or intramuscular shot of a synthetic 15-amino-acid peptide, a fragment derived from a protein found in human gastric juice. It arrives as a freeze-dried (lyophilized) powder in a small glass vial and has to be mixed with a liquid before it can go into a syringe. That mixing step is called reconstitution, and it's the part most people get wrong or worry about most. The peptide itself has been studied for decades in animal models, mostly out of one research group in Croatia, looking at gut healing, tendon and ligament repair, and blood vessel formation ^[1][2]. More recent reviews, including a 2025 literature and patent review, describe it as having many studied biological activities in preclinical work, from tissue protection to modulation of nitric oxide signaling ^[1]. None of that preclinical breadth has yet translated into an approved product you can get at a retail pharmacy. Anyone selling you an injection product is operating in the research-chemical or compounding space, not the approved-drug space. For background on how the peptide is studied and what the research record actually contains, see our main BPC-157 evidence overview.

How do you reconstitute BPC-157 for injection

Reconstitution means adding a sterile liquid, almost always bacteriostatic water, to the lyophilized powder in the vial. You don't dump it in fast. You let the water run down the inside of the glass and swirl gently, because injecting agitation can shear the peptide chain apart. The basic steps people follow: wipe the vial top with an alcohol swab, draw the bacteriostatic water into a syringe, insert the needle at an angle so the stream hits the glass wall instead of the powder directly, and let it dissolve on its own or with a gentle swirl (never shake). A 5 mg vial reconstituted with 2 mL of water gives a concentration of 2.5 mg/mL, which is a common starting point people use to make the math for insulin-syringe unit doses easier, but there's no clinical trial establishing that ratio as ideal; it's just a common convenience convention, not a dosing standard from a trial. Once reconstituted, the vial needs refrigeration and is generally treated as good for a limited window (commonly cited informally as 2 to 4 weeks refrigerated), because bacteriostatic water only slows microbial growth, it doesn't guarantee the peptide stays fully intact indefinitely. None of this reconstitution protocol comes from a published clinical trial. It's practical handling guidance carried over from compounding pharmacy norms and injectable-peptide handling in general, not a tested stability study specific to BPC-157.

How do you mix a BPC-157 and TB-500 blend

A BPC-157 / TB-500 blend is two separate peptides combined in one vial, or dosed from two vials drawn into the same syringe, on the idea that they act on different aspects of tissue repair (BPC-157 more on angiogenesis and local tissue signaling, TB-500 as a synthetic fragment of thymosin beta-4 studied for actin regulation and cell migration in animal models). There is no published human trial testing the combination against either peptide alone. Mechanically, a bpc-157 tb-500 blend reconstitution follows the same rule as reconstituting either peptide alone: bacteriostatic water, slow stream down the vial wall, gentle swirl, refrigerate after mixing. If you're buying a pre-blended vial from a compounding source, the concentration ratio is fixed by the pharmacy and you just add water to the stated volume on the label. If you're combining two separate single-peptide vials yourself, you're now stacking two unregulated variables (dose accuracy of each peptide plus interaction effects) with zero controlled data behind the combination. That's worth being honest about: this is a popular practice online, but it is a practice built on inference from separate rodent literatures, not on a blend-specific trial. For a side-by-side look at what's actually been studied for each peptide individually, see our BPC-157 vs TB-500 comparison.

What injection sites and methods are used in the research

In the rodent literature, BPC-157 has most often been given by intraperitoneal or subcutaneous injection, or applied locally to damaged tendon, ligament, or bone tissue in surgical models ^[2][3]. A 2011 study in the Journal of Applied Physiology, for example, looked at BPC-157's effect on tendon healing in a rat model, examining cell survival, migration, and outgrowth in explanted tendon fibroblasts and in vivo tendon-to-bone healing, not human tendon patients ^[3]. The human data that exists uses a different route entirely: intra-articular injection, meaning directly into a joint space. A 2021 report in Alternative Therapies in Health and Medicine described intra-articular BPC-157 injections for several categories of knee pain, framed as a small clinical series rather than a randomized controlled trial ^[4]. That is a meaningfully different clinical context than the subcutaneous, at-home self-injection approach most people researching this online are actually asking about. Nobody has published a controlled human trial on subcutaneous BPC-157 injection for tendon or muscle injury specifically. That gap is worth sitting with before assuming the rodent tendon data predicts what a subcutaneous shot does in a person's shoulder or Achilles. For dosing conventions people commonly reference (again, not clinically validated for humans), see our BPC-157 dosage guide and the accompanying dosage calculator.

What does the animal research actually show

This is the bulk of the BPC-157 literature, and it's worth being precise about what's in it rather than waving at it generally. A 2019 review in Cell and Tissue Research covers BPC-157's studied role in accelerating musculoskeletal soft tissue healing, drawing on animal models of tendon, ligament, muscle, and bone injury ^[5]. A 2018 paper in Current Pharmaceutical Design compared BPC-157's effects to standard angiogenic growth factors in models of gastrointestinal tract healing, tendon, ligament, muscle, and bone repair, arguing the peptide's activity overlaps with known vascular growth factor pathways ^[2]. A separate 2014 paper in the same journal, BPC 157 and blood vessels, describes the peptide's studied relationship to new blood vessel formation (angiogenesis) in animal tissue injury models ^[6], which is the proposed mechanism behind most of the tissue-healing claims you'll see repeated online. A 2021 review in Frontiers in Pharmacology specifically covers BPC-157 and wound healing, again built from animal wound models [5,6]. None of these papers involve human tissue biopsy confirmation or human wound-healing trials. They are consistent, and the mechanism story (angiogenesis, growth factor pathway interaction) holds together across multiple animal studies from overlapping research groups, but consistency across rodent studies is not the same evidentiary weight as a human randomized trial. Say that plainly every time someone shows you a rat tendon photo as proof of anything in a person.

What does the human evidence actually show

Small, early, and narrow. That's the honest three-word summary. The most direct human data point is a 2024 pilot study in Alternative Therapies in Health and Medicine testing BPC-157 for symptoms in patients with interstitial cystitis, a chronic bladder condition ^[7]. It's described as a pilot study, which in research language means small sample size, no large confirmatory trial, and results meant to justify (or not) a bigger study, not to establish an approved treatment. The 2021 intra-articular knee injection report is the other concrete human data point, again framed as a small clinical series covering multiple types of knee pain rather than one diagnosis ^[4]. Beyond those two, a 2025 systematic review in the HSS Journal looked specifically at BPC-157's emerging use in orthopaedic sports medicine, and a 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled 'Regeneration or Risk?', took stock of the same territory ^[8][9]. Systematic and narrative reviews summarize existing literature; they don't generate new patient data themselves, and both of these reviews are working from a research base that is still overwhelmingly preclinical. A 2026 primer in JAAOS Global Research & Reviews on therapeutic peptides in orthopaedics, and a 2026 review in Sports Medicine on the safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injury, both frame BPC-157 as a peptide under active investigation with an evidence base that has not yet reached the human trial size or rigor needed for approval ^[10][11]. That's the accurate state of things as of this review, not a settled verdict either for or against.

Is BPC-157 legal to buy and inject

Not as an approved drug, no. There is no BPC-157 product listed in Drugs@FDA, the FDA's database of approved drug products . That means no version of it has gone through the FDA approval process for safety and efficacy in humans. The legal channel some people point to is pharmacy compounding under section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, which lets licensed pharmacies prepare custom medications for individual patients under specific conditions ^[12]. But compounding a substance legally requires that substance to be on FDA's approved bulks lists, found in 21 CFR 216.23 for 503A pharmacies and 21 CFR 216.24 for 503B outsourcing facilities ^[13][14]. BPC-157 has been the subject of FDA nomination review for these bulk drug substance lists, and its regulatory status has shifted over time; FDA maintains guidance describing that nomination and review process . The practical upshot: sourcing through a licensed compounding pharmacy that is actually following current FDA bulk-substance guidance is a meaningfully different risk profile than buying an unlabeled vial off a research-chemical website that ships with a 'not for human consumption' disclaimer. For a closer look at where BPC-157 currently sits legally and what 'for sale' actually means in this market, see our BPC-157 for sale page.

What are the safety risks and side effects of BPC-157 injections

Nobody has run a large, controlled human safety trial on BPC-157 injections, so any side effect list you see is built from small human reports, animal toxicology, and general injectable-peptide risk, not a Phase 3 safety database. The injection itself carries the ordinary risks of any subcutaneous or intramuscular shot: injection site redness, bruising, or infection risk if sterile technique isn't followed. Sourcing quality is a real variable here; peptide from an unverified vendor can have incorrect concentration, contamination, or breakdown products, and there's no FDA inspection guarantee behind most of what's sold online. A 2026 review in Sports Medicine on approved versus unapproved peptide therapies specifically frames this safety-versus-efficacy gap as an open problem for the field, not something resolved in BPC-157's favor or against it ^[11]. A 2025 narrative review titled 'Regeneration or Risk?' uses that framing deliberately: the same angiogenic (blood vessel growth promoting) mechanism proposed as the healing benefit is also the mechanism that raises theoretical concern about promoting unwanted tissue growth, and the review calls for more rigorous human data before drawing firm conclusions either way ^[9]. For the fuller rundown of documented and theoretical side effects, see our BPC-157 side effects page.

How is BPC-157 dosed in practice, and where do those numbers come from

Most dosing figures you'll see online (measured in micrograms, often 200 to 500 mcg per injection, once or twice daily) are carried over from research-chemical vendor convention and informal user reports, not from a published human dose-finding trial. There is no approved human dosing standard because there is no approved product. Animal studies use body-weight-scaled doses (often expressed in micrograms per kilogram) that are not directly convertible to a flat human dose by simple math, and no paper in this research pack validates a specific milligram target for human subcutaneous self-injection. The intra-articular knee study and the interstitial cystitis pilot study each used their own protocol-specific doses suited to their delivery route and condition, not a general-purpose number ^[4][7]. If you're trying to work out a starting point from a reconstituted vial's concentration, our dosage calculator and full dosage guide walk through the math people commonly use, with the same caveat repeated: this is convention, not clinical guidance. When you reconstitute BPC-157 at home, the concentration you land on determines every subsequent dosing decision, so getting that math right matters more than debating which micrograms number is 'correct.'

What conditions is BPC-157 being studied for

The studied territory, again pulling only from named papers, splits into three buckets: gastrointestinal healing (the peptide's namesake origin, tied to gastric protection), musculoskeletal soft tissue repair (tendon, ligament, muscle, bone), and a smaller emerging bucket of specific human pilot applications. Musculoskeletal repair is the most active current research area, covered across a 2025 HSS Journal systematic review of orthopaedic sports medicine applications, a 2018 Current Pharmaceutical Design comparison to angiogenic growth factors across tendon/ligament/muscle/bone models, and a 2019 Cell and Tissue Research review of soft tissue healing mechanisms ^[8][2][5]. A 2026 JAAOS Global Research & Reviews paper frames BPC-157 within a broader look at therapeutic peptides in orthopaedics generally, alongside other peptides under investigation, discussing applications, challenges, and open questions for the field rather than confirming BPC-157 specifically as ready for clinical use ^[10]. Outside orthopaedics, the interstitial cystitis pilot study is the clearest non-musculoskeletal human application on record ^[7]. Wound healing broadly (skin, soft tissue) is covered in the 2021 Frontiers in Pharmacology review, again built from animal wound models ^[15].

How does BPC-157 compare to other peptides used for injury recovery

TB-500 (thymosin beta-4 fragment) is the peptide most commonly stacked or compared with BPC-157, on the theory that it works through cell migration and actin regulation rather than the angiogenesis-focused mechanism proposed for BPC-157. Neither peptide has an approved drug product, and neither has a large human trial behind its injury-recovery use. | Peptide | Primary studied mechanism | Human trial evidence | Approved drug product |

What should you actually do if you're considering a BPC-157 injection

Be honest with yourself about which evidence tier you're relying on. If you're picturing the rat tendon-healing studies as proof this will fix your Achilles, that's a category error; those are animal data points suggesting a mechanism worth studying in people, not a guarantee for your body ^[3][5]. If you're going to pursue it anyway, sourcing is the single highest-leverage decision you control. A licensed compounding pharmacy operating within current FDA bulk-substance rules is a fundamentally different risk profile than an unlabeled vial from a research-chemical site with no batch testing disclosed. BPC-157 Co works with a provider-reviewed process fulfilled through a licensed compounding pharmacy partner, rather than compounding anything itself, which is the structure worth looking for regardless of which brand you use: a provider reviewing your situation, and a licensed pharmacy actually preparing the product. Ask any source directly: can you show me a certificate of analysis for this specific batch? Is this compounded by a licensed 503A or 503B pharmacy? Reconstitute with bacteriostatic water, not plain sterile water if you want any preservative benefit, keep it refrigerated, and don't push past the 2 to 4 week informal shelf-life window most compounding guidance suggests for reconstituted peptide vials.

Frequently asked questions

How do you reconstitute BPC-157 powder for injection?

Add bacteriostatic water to the freeze-dried powder by letting it run slowly down the inside of the vial, then swirl gently (never shake) until dissolved. A common convention is 2 mL of water per 5 mg vial for a 2.5 mg/mL concentration, though this ratio comes from vendor and user convention, not a published clinical protocol.

How long does reconstituted BPC-157 last once mixed?

Reconstituted peptide is commonly stored refrigerated and used within roughly 2 to 4 weeks, based on general injectable-peptide handling norms rather than a BPC-157-specific stability trial. Bacteriostatic water slows bacterial growth but doesn't guarantee the peptide itself stays fully intact indefinitely, so treat older vials with caution.

Can you mix BPC-157 and TB-500 in the same syringe?

People do combine them, and pre-blended vials exist from some compounding sources, but no published human trial has tested the combination against either peptide alone. Reconstitution follows the same bacteriostatic-water method as either peptide individually; the added risk is stacking two unregulated dosing variables rather than one.

Is BPC-157 FDA approved?

No. There is no BPC-157 product listed in Drugs@FDA, the FDA's approved drug products database. Any BPC-157 you can obtain comes through pharmacy compounding channels or unregulated research-chemical sellers, not an approved prescription drug pathway.

Is it legal to buy BPC-157 through a compounding pharmacy?

Compounding pharmacies operate under 21 U.S.C. 353a and must use substances on FDA's approved bulk drug lists under 21 CFR 216.23 (503A) or 216.24 (503B). BPC-157's status on these lists has been under FDA nomination review and has shifted over time, so legality depends on current list status and how the specific pharmacy is operating.

What does the human research on BPC-157 actually show?

Human evidence is limited to small studies: a 2024 pilot study on interstitial cystitis symptoms and a 2021 report on intra-articular knee injections for multiple pain types. Both are small and early. No large randomized controlled trial in humans has been published for BPC-157 injections.

Does BPC-157 heal tendons and ligaments in humans?

That claim comes from rodent studies, including a 2011 Journal of Applied Physiology paper on tendon healing and a 2019 Cell and Tissue Research review of musculoskeletal soft tissue healing, both animal work. No published human trial confirms tendon or ligament healing from BPC-157 injection.

What injection site is used for BPC-157?

Animal studies commonly use intraperitoneal, subcutaneous, or local application to the injured tissue. The one human study category on record used intra-articular (into the joint) injection for knee pain. Subcutaneous self-injection, the most common practice online, has not been studied in a published human trial.

What are the side effects of BPC-157 injections?

No large human safety trial exists, so documented side effects come from small studies, injection-site risk generally, and theoretical concerns raised in review papers about the peptide's angiogenic (blood vessel growth) mechanism. Sourcing quality (contamination, incorrect concentration) is a separate practical risk from unverified vendors.

How much BPC-157 should you inject?

There is no clinically validated human dose. Commonly cited figures (200 to 500 mcg per injection) come from vendor convention and user reports, not a published dose-finding trial. Animal studies use body-weight-scaled doses that don't convert directly to a human number.

What is the difference between BPC-157 and TB-500?

Both are peptides studied in animal models for tissue repair, but through different proposed mechanisms: BPC-157 through angiogenesis and growth factor pathway interaction, TB-500 through actin regulation and cell migration. Neither has drug approval or a large human trial, and no head-to-head human comparison exists.

Can BPC-157 be used for gut or digestive issues?

BPC-157 was originally studied as a gastric-derived peptide with gut-protective effects in animal models, which is where its name comes from (body protection compound). Human trial data on digestive applications specifically is not part of the current published record covered in major recent reviews.

Where does BPC-157 come from and how is it studied?

BPC-157 is a synthetic 15-amino-acid fragment derived from a protective protein found in human gastric juice. The great majority of research on it is preclinical, conducted in rodent models, primarily by one research group, studying tissue repair, angiogenesis, and gut protection mechanisms.

Sources

1. PubMed, Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review, Pharmaceuticals (Basel), 2025: 2025 literature and patent review describing BPC-157's studied biological activities across preclinical work
2. PubMed, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal, 2025: 2025 systematic review of BPC-157 use in orthopaedic sports medicine
3. PubMed, Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing, Cell and Tissue Research, 2019: 2019 review of BPC-157's role in musculoskeletal soft tissue healing in animal models
4. PubMed, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain, Alternative Therapies in Health and Medicine, 2021: 2021 human report on intra-articular BPC-157 injection for multiple types of knee pain
5. PubMed, BPC 157 and Standard Angiogenic Growth Factors, Current Pharmaceutical Design, 2018: 2018 paper comparing BPC-157 to standard angiogenic growth factors across GI, tendon, ligament, muscle, and bone healing models
6. PubMed, Stable Gastric Pentadecapeptide BPC 157 and Wound Healing, Frontiers in Pharmacology, 2021: 2021 review of BPC-157 and wound healing based on animal wound models
7. PubMed, Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, Current Reviews in Musculoskeletal Medicine, 2025: 2025 narrative review weighing BPC-157's regenerative potential against theoretical risks from its angiogenic mechanism
8. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions, JAAOS Global Research & Reviews, 2026: 2026 review discussing BPC-157 within broader orthopaedic peptide therapy applications, challenges, and open questions
9. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance, Sports Medicine, 2026: 2026 review framing the safety-versus-efficacy gap for unapproved peptide therapies including BPC-157
10. PubMed, The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration, Journal of Applied Physiology, 2011: 2011 rat study on BPC-157's effect on tendon fibroblast survival, migration, and outgrowth
11. PubMed, BPC 157 and blood vessels, Current Pharmaceutical Design, 2014: 2014 paper describing BPC-157's studied relationship to angiogenesis in animal tissue injury models
12. PubMed, Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study, Alternative Therapies in Health and Medicine, 2024: 2024 human pilot study testing BPC-157 for interstitial cystitis symptoms
13. eCFR, 21 CFR 216.23, the 503A Bulks List: Federal regulation listing bulk drug substances approved for 503A pharmacy compounding
14. eCFR, 21 CFR 216.24, the 503B Bulks List: Federal regulation listing bulk drug substances approved for 503B outsourcing facility compounding
15. Cornell Legal Information Institute, 21 U.S.C. 353a: Statute governing pharmacy compounding conditions under section 503A of the FDCA
16. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA guidance describing the nomination and review process for bulk substances including BPC-157
17. FDA, Drugs@FDA database: No BPC-157 product is listed as an FDA-approved drug